Laura K. Fishwick

Counsel
Fishwick Laura

Laura Fishwick is experienced with Hatch-Waxman Act patent litigation and contested proceedings before the U. S. Patent and Trademark Office. Laura also has experience handling due diligence investigations, opinion work, and pre-lawsuit investigations. She has counseled on a wide range of chemical and life science patent matters involving small-molecule pharmaceuticals, formulations, polymorphs, and methods of treatment.

Experience

Representative Matters

  • Represented Novartis in Novartis v. BreckenridgeWest-Ward and Par (Zortress® (everolimus) for kidney and liver transplants) (D. Del., Fed. Cir., PTAB-IPR)
  • Represented Novartis in Novartis v. West-Ward (Afinitor® (everolimus) for renal cell carcinoma and pancreatic neuroendocrine tumors) (D. Del., Fed. Cir., PTAB-IPR)
  • Represented Novartis in Novartis v. Par (Afinitor® (everolimus) for breast cancer) (D. Del.)
  • Represented Novartis in Novartis v. Breckenridge (Afinitor® (everolimus) for renal cell carcinoma, renal angiomyolipoma, and tuberous sclerosis complex with subependymal giant cell astrocytoma) (D. Del., PTAB-IPR)
  • Represented Novartis in Novartis v. Mylan (Afinitor® Disperz (everolimus) for tuberous sclerosis complex with subependymal giant cell astrocytoma) (D. Del.)

Representative Clients

  • Novartis

Insights

Credentials
+

Education

  • J.D. Harvard Law School 2013
    • Digest submissions editor, Harvard Journal of Law and Technology
  • B.S. Biochemistry and Molecular Biology summa cum laude University of Florida 2010

Bar Admissions

  • New York
  • U.S. Patent and Trademark Office

Court Admissions

  • Southern District of New York
  • U.S. Court of Appeals for the Federal Circuit

Recognition
+

  • The Best Lawyers in America, Ones to Watch, 2021 – 2022